|
ISSN 1977-0987 |
||
|
Il-Ġurnal Uffiċjali tal-Unjoni Ewropea |
C 232 |
|
|
||
|
Edizzjoni bil-Malti |
Informazzjoni u Avviżi |
Volum 66 |
|
Werrej |
Paġna |
|
|
|
IV Informazzjoni |
|
|
|
INFORMAZZJONI MINN ISTITUZZJONIJIET, KORPI, UFFIĊĊJI U AĠENZIJI TAL-UNJONI EWROPEA |
|
|
|
Il-Kummissjoni Ewropea |
|
|
2023/C 232/01 |
|
MT |
|
IV Informazzjoni
INFORMAZZJONI MINN ISTITUZZJONIJIET, KORPI, UFFIĊĊJI U AĠENZIJI TAL-UNJONI EWROPEA
Il-Kummissjoni Ewropea
|
30.6.2023 |
MT |
Il-Ġurnal Uffiċjali tal-Unjoni Ewropea |
C 232/1 |
Sommarju ta’ deċiżjonijiet tal-Unjoni Ewropea dwar l-awtorizzazzjonijiet għat-tqegħid fis-suq tal-prodotti mediċinali mill-1 ta’ Mejju 2023 sal-31 ta’ Mejju 2023
(Ippubblikat skont l-Artikolu 13 jew l-Artikolu 38 tar-Regolament (KE) Nru 726/2004 tal-Parlament Ewropew u tal-Kunsill (1) jew L-Artikolu 5 tar-Regolament (UE) 2019/6 tal-Parlament Ewropew u tal-Kunsill (2))
(2023/C 232/01)
|
— |
Ħruġ ta’ awtorizzazzjoni għat-tqegħid fis-suq (Artikolu 13 tar-Regolament (KE) Nru 726/2004 tal-Parlament Ewropew u tal-Kunsill): Aċċettat |
|
Data tad-deċiżjoni |
Isem tal-prodott mediċinali |
INN (Denominazzjoni Internazzjonali Komuni) |
Detentur tal-awtorizzazzjoni għat-tqegħid fis-suq |
Numru tal-entrata fir-Reġistru Komunitarju |
Forma farmaċewtika |
Kodiċi ATC (Kodiċi Anatomiku Terapewtiku Kimiku) |
Data ta’ notifika |
||
|
4.5.2023 |
Elfabrio |
pegunigalsidase alfa |
|
EU/1/23/1724 |
Konċentrat għal soluzzjoni għal infużjoni |
A16AB20 |
5.5.2023 |
||
|
4.5.2023 |
Tibsovo |
ivosidenib |
|
EU/1/23/1728 |
Pillola miksija b’rita |
L01XX62 |
8.5.2023 |
||
|
15.5.2023 |
Hyftor |
sirolimus |
|
EU/1/23/1723 |
Ġel |
L04AA10 |
26.5.2023 |
||
|
26.5.2023 |
Dabigatran Etexilate Accord |
dabigatran etexilate |
|
EU/1/22/1665 |
Kapsula, iebsa |
B01AE07 |
30.5.2023 |
||
|
26.5.2023 |
Epysqli |
eculizumab |
|
EU/1/23/1735 |
Konċentrat għal soluzzjoni għal infużjoni |
L04AA25 |
31.5.2023 |
||
|
26.5.2023 |
Omvoh |
mirikizumab |
|
EU/1/23/1736 |
Konċentrat għal soluzzjoni għal infużjoni Soluzzjoni għall-injezzjoni |
L04AC |
30.5.2023 |
||
|
26.5.2023 |
Pedmarqsi |
tijosulfat tas-sodju |
|
EU/1/23/1734 |
Soluzzjoni għal infużjoni |
Pending |
5.6.2023 |
||
|
26.5.2023 |
Qaialdo |
spironolatton |
|
EU/1/23/1731 |
Suspensjoni Orali |
C03DA01 |
31.5.2023 |
||
|
26.5.2023 |
Sugammadex Adroiq |
sugammadex |
|
EU/1/23/1733 |
Soluzzjoni għall-injezzjoni |
V03AB35 |
30.5.2023 |
||
|
31.5.2023 |
Briumvi |
ublituximab |
|
EU/1/23/1730 |
Konċentrat għal soluzzjoni għal infużjoni |
L04AG14 |
1.6.2023 |
||
|
31.5.2023 |
Lacosamide Adroiq |
Lacosamide |
|
EU/1/23/1732 |
Soluzzjoni għal infużjoni |
N03AX18 |
1.6.2023 |
|
— |
Modifika ta’ awtorizzazzjoni għat-tqegħid fis-suq (Artikolu 13 tar-Regolament (KE) Nru 726/2004 tal-Parlament Ewropew u tal-Kunsill): Aċċettat |
|
Data tad-deċiżjoni |
Isem tal-prodott mediċinali |
Detentur tal-awtorizzazzjoni għat-tqegħid fis-suq |
Numru tal-entrata fir-Reġistru Komunitarju |
Data ta' notifika |
||
|
2.5.2023 |
Tecfidera |
|
EU/1/13/837 |
3.5.2023 |
||
|
4.5.2023 |
Carmustine Obvius |
|
EU/1/18/1278 |
5.5.2023 |
||
|
4.5.2023 |
Fampridine Accord |
|
EU/1/20/1477 |
5.5.2023 |
||
|
4.5.2023 |
Leflunomide medac |
|
EU/1/10/637 |
8.5.2023 |
||
|
4.5.2023 |
Nityr |
|
EU/1/18/1290 |
5.5.2023 |
||
|
4.5.2023 |
Riltrava Aerosphere |
|
EU/1/21/1604 |
5.5.2023 |
||
|
5.5.2023 |
Arsenic trioxide Mylan |
|
EU/1/20/1427 |
8.5.2023 |
||
|
5.5.2023 |
Benlysta |
|
EU/1/11/700 |
9.5.2023 |
||
|
5.5.2023 |
Gazyvaro |
|
EU/1/14/937 |
8.5.2023 |
||
|
5.5.2023 |
Leflunomide ratiopharm |
|
EU/1/10/654 |
9.5.2023 |
||
|
5.5.2023 |
Leflunomide Zentiva |
|
EU/1/09/604 |
8.5.2023 |
||
|
5.5.2023 |
OXERVATE |
|
EU/1/17/1197 |
8.5.2023 |
||
|
5.5.2023 |
Pritor |
|
EU/1/98/089 |
8.5.2023 |
||
|
5.5.2023 |
Rivastigmine Actavis |
|
EU/1/11/693 |
8.5.2023 |
||
|
5.5.2023 |
Samsca |
|
EU/1/09/539 |
10.5.2023 |
||
|
5.5.2023 |
Temozolomide Teva |
|
EU/1/09/606 |
8.5.2023 |
||
|
5.5.2023 |
Ultomiris |
|
EU/1/19/1371 |
15.5.2023 |
||
|
5.5.2023 |
Vfend |
|
EU/1/02/212 |
8.5.2023 |
||
|
5.5.2023 |
Waylivra |
|
EU/1/19/1360 |
12.5.2023 |
||
|
15.5.2023 |
Firazyr |
|
EU/1/08/461 |
25.5.2023 |
||
|
15.5.2023 |
Lenvima |
|
EU/1/15/1002 |
16.5.2023 |
||
|
15.5.2023 |
Nexavar |
|
EU/1/06/342 |
16.5.2023 |
||
|
15.5.2023 |
Selincro |
|
EU/1/12/815 |
22.5.2023 |
||
|
15.5.2023 |
Tenkasi |
|
EU/1/15/989 |
16.5.2023 |
||
|
15.5.2023 |
TRIXEO AEROSPHERE |
|
EU/1/20/1498 |
16.5.2023 |
||
|
15.5.2023 |
Veltassa |
|
EU/1/17/1179 |
16.5.2023 |
||
|
23.5.2023 |
Arsenic Trioxide Accord |
|
EU/1/19/1398 |
24.5.2023 |
||
|
23.5.2023 |
Javlor |
|
EU/1/09/550 |
31.5.2023 |
||
|
23.5.2023 |
Levetiracetam Actavis Group |
|
EU/1/11/738 |
24.5.2023 |
||
|
23.5.2023 |
Rhokiinsa |
|
EU/1/19/1400 |
25.5.2023 |
||
|
26.5.2023 |
AYVAKYT |
|
EU/1/20/1473 |
30.5.2023 |
||
|
26.5.2023 |
BLENREP |
|
EU/1/20/1474 |
30.5.2023 |
||
|
26.5.2023 |
Cosentyx |
|
EU/1/14/980 |
31.5.2023 |
||
|
26.5.2023 |
Defitelio |
|
EU/1/13/878 |
30.5.2023 |
||
|
26.5.2023 |
Emtricitabine/Tenofovir disoproxil Mylan |
|
EU/1/16/1133 |
31.5.2023 |
||
|
26.5.2023 |
Entresto |
|
EU/1/15/1058 |
31.5.2023 |
||
|
26.5.2023 |
IBRANCE |
|
EU/1/16/1147 |
30.5.2023 |
||
|
26.5.2023 |
Jardiance |
|
EU/1/14/930 |
31.5.2023 |
||
|
26.5.2023 |
Kanuma |
|
EU/1/15/1033 |
6.6.2023 |
||
|
26.5.2023 |
Kentera |
|
EU/1/03/270 |
31.5.2023 |
||
|
26.5.2023 |
Levetiracetam ratiopharm |
|
EU/1/11/702 |
31.5.2023 |
||
|
26.5.2023 |
Levetiracetam SUN |
|
EU/1/11/741 |
6.6.2023 |
||
|
26.5.2023 |
Lojuxta |
|
EU/1/13/851 |
30.5.2023 |
||
|
26.5.2023 |
Luveris |
|
EU/1/00/155 |
30.5.2023 |
||
|
26.5.2023 |
Neparvis |
|
EU/1/16/1103 |
31.5.2023 |
||
|
26.5.2023 |
Nerlynx |
|
EU/1/18/1311 |
30.5.2023 |
||
|
26.5.2023 |
OBIZUR |
|
EU/1/15/1035 |
30.5.2023 |
||
|
26.5.2023 |
Onpattro |
|
EU/1/18/1320 |
31.5.2023 |
||
|
26.5.2023 |
Oxbryta |
|
EU/1/21/1622 |
5.6.2023 |
||
|
26.5.2023 |
QUVIVIQ |
|
EU/1/22/1638 |
2.6.2023 |
||
|
26.5.2023 |
Replagal |
|
EU/1/01/189 |
30.5.2023 |
||
|
26.5.2023 |
Ronapreve |
|
EU/1/21/1601 |
30.5.2023 |
||
|
26.5.2023 |
RXULTI |
|
EU/1/18/1294 |
7.6.2023 |
||
|
26.5.2023 |
Spikevax |
|
EU/1/20/1507 |
30.5.2023 |
||
|
26.5.2023 |
Vemlidy |
|
EU/1/16/1154 |
30.5.2023 |
||
|
31.5.2023 |
Adempas |
|
EU/1/13/907 |
1.6.2023 |
||
|
31.5.2023 |
Advagraf |
|
EU/1/07/387 |
6.6.2023 |
||
|
31.5.2023 |
Bimzelx |
|
EU/1/21/1575 |
1.6.2023 |
||
|
31.5.2023 |
Bylvay |
|
EU/1/21/1566 |
3.6.2023 |
||
|
31.5.2023 |
Cinacalcet Accordpharma |
|
EU/1/20/1429 |
1.6.2023 |
||
|
31.5.2023 |
Koselugo |
|
EU/1/21/1552 |
1.6.2023 |
||
|
31.5.2023 |
Kovaltry |
|
EU/1/15/1076 |
1.6.2023 |
||
|
31.5.2023 |
Libmeldy |
|
EU/1/20/1493 |
5.6.2023 |
||
|
31.5.2023 |
OPDIVO |
|
EU/1/15/1014 |
1.6.2023 |
||
|
31.5.2023 |
Rekovelle |
|
EU/1/16/1150 |
2.6.2023 |
||
|
31.5.2023 |
Tecovirimat SIGA |
|
EU/1/21/1600 |
6.6.2023 |
||
|
31.5.2023 |
Ultomiris |
|
EU/1/19/1371 |
5.6.2023 |
||
|
31.5.2023 |
Viread |
|
EU/1/01/200 |
1.6.2023 |
||
|
31.5.2023 |
Yervoy |
|
EU/1/11/698 |
1.6.2023 |
||
|
31.5.2023 |
Zejula |
|
EU/1/17/1235 |
7.6.2023 |
||
|
31.5.2023 |
Zostavax |
|
EU/1/06/341 |
7.6.2023 |
||
|
31.5.2023 |
Zyllt |
|
EU/1/09/553 |
2.6.2023 |
|
— |
Ħruġ ta’ awtorizzazzjoni għat-tqegħid fis-suq (Artikolu 38 tar-Regolament (KE) Nru 726/2004 tal-Parlament Ewropew u tal-Kunsill; l-Artikolu 5 tar-Regolament (UE) 2019/6 tal-Parlament Ewropew u tal-Kunsill): Aċċettat |
|
Data tad-deċiżjoni |
Isem tal-prodott mediċinali |
INN (Denominazzjoni Internazzjonali Komuni) |
Detentur tal-awtorizzazzjoni għat-tqegħid fis-suq |
Numru tal-entrata fir-Reġistru Komunitarju |
Forma farmaċewtika |
Kodiċi ATC (Kodiċi Anatomiku Terapewtiku Kimiku) |
Data ta' notifika |
||
|
16.5.2023 |
Newflend ND H9 |
Il-marda ta' Newcastle u l-vaċċin kontra l-Influwenza Avjarja (ħaj, rikombinanti) |
|
EU/2/23/296 |
Konċentrat u solvent għal suspensjoni għal injezzjoni |
QI01AD |
17.5.2023 |
|
— |
Modifika ta’ awtorizzazzjoni għat-tqegħid fis-suq (Artikolu 38 tar-Regolament (KE) Nru 726/2004 tal-Parlament Ewropew u tal-Kunsill; l-Artikolu 5 tar-Regolament (UE) 2019/6 tal-Parlament Ewropew u tal-Kunsill): Aċċettat |
|
Data tad-deċiżjoni |
Isem tal-prodott mediċinali |
Detentur tal-awtorizzazzjoni għat-tqegħid fis-suq |
Numru tal-entrata fir-Reġistru Komunitarju |
Data ta' notifika |
||
|
4.5.2023 |
Bravecto Plus |
|
EU/2/18/224 |
5.5.2023 |
||
|
4.5.2023 |
Equilis West Nile |
|
EU/2/13/151 |
5.5.2023 |
||
|
4.5.2023 |
Innovax-ILT |
|
EU/2/15/182 |
5.5.2023 |
||
|
4.5.2023 |
Prevomax |
|
EU/2/17/211 |
15.5.2023 |
||
|
4.5.2023 |
Versican Plus L4 |
|
EU/2/14/171 |
5.5.2023 |
||
|
16.5.2023 |
Bravecto |
|
EU/2/13/158 |
17.5.2023 |
||
|
16.5.2023 |
Dany's BienenWohl |
|
EU/2/18/225 |
17.5.2023 |
||
|
16.5.2023 |
NexGard Combo |
|
EU/2/20/267 |
19.5.2023 |
||
|
16.5.2023 |
Nobilis Influenza H5N2 |
|
EU/2/06/061 |
17.5.2023 |
||
|
16.5.2023 |
Porcilis PCV M Hyo |
|
EU/2/14/175 |
22.5.2023 |
||
|
16.5.2023 |
Poulvac E. coli |
|
EU/2/12/140 |
22.5.2023 |
||
|
16.5.2023 |
Stronghold |
|
EU/2/99/014 |
17.5.2023 |
||
|
16.5.2023 |
Versican Plus Pi |
|
EU/2/14/168 |
17.5.2023 |
||
|
16.5.2023 |
Versican Plus Pi/L4 |
|
EU/2/14/172 |
17.5.2023 |
||
|
26.5.2023 |
Purevax RCPCh FeLV |
|
EU/2/04/047 |
30.5.2023 |
||
|
26.5.2023 |
Suvaxyn PRRS MLV |
|
EU/2/17/215 |
30.5.2023 |
||
|
26.5.2023 |
Syvazul BTV |
|
EU/2/18/231 |
30.5.2023 |
||
|
26.5.2023 |
UBAC |
|
EU/2/18/227 |
5.6.2023 |
||
|
26.5.2023 |
Vaxxitek HVT + IBD |
|
EU/2/02/032 |
30.5.2023 |
|
— |
Irtirar ta’ awtorizzazzjoni għat-tqegħid fis-suq (Artikolu 38 tar-Regolament (KE) Nru 726/2004 tal-Parlament Ewropew u tal-Kunsill; l-Artikolu 5 tar-Regolament (UE) 2019/6 tal-Parlament Ewropew u tal-Kunsill) |
|
Data tad-deċiżjoni |
Isem tal-prodott mediċinali |
Detentur tal-awtorizzazzjoni għat-tqegħid fis-suq |
Numru tal-entrata fir-Reġistru Komunitarju |
Data ta' notifika |
||
|
16.5.2023 |
Aftovaxpur Doe |
|
EU/2/13/153 |
19.5.2023 |
||
|
16.5.2023 |
Comfortis |
|
EU/2/10/115 |
30.5.2023 |
Kull min jixtieq jikkonsulta r-rapport ta' evalwazzjoni pubblika dwar il-prodotti mediċinali kkonċernati u d-deċiżjonijiet marbuta magħhom għandu jikkuntattja lil:
|
European Medicines Agency |
|
Domenico Scarlattilaan 6 |
|
1083 HS Amsterdam |
|
NETHERLANDS |